What’s Up with U.S. Merger Remedies? A Podcast Episode Featuring Jeny Maier
February 26, 2024, 3:14 PM
By: Axinn Insights
The US antitrust agencies’ approach to merger remedies has undergone a significant change under the Biden administration. Remedies are increasingly disfavored.
Axinn's Managing Partner Jeny Maier joins Dan Ducore, former Assistant Director of the Federal Trade Commission’s Bureau of Competition Compliance Division, and co-host Barry Nigro on Our Curious Amalgam to discuss the growing skepticism towards merger remedies by the US antitrust authorities.
Listen to this episode to learn more about whether merger remedies remain a viable option in the US and, if so, how parties should approach them given the government’s current hostility toward remedies.
To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
30th Annual IBA Competition Conference
Speaking Engagement
Antitrust
What Happens in Vegas Stays in Vegas: Third Circuit Parts Ways with Ninth Circuit and Reinstates Atlantic City Algorithmic-Pricing Claim
Axinn Viewpoints
Antitrust
What Should Directors Be Asking? Antitrust in the Boardroom
Podcast
Antitrust
Axinn Represents Modular in $4 Billion Acquisition by Qualcomm
Deals & Cases
Antitrust
Will New DOJ Timing Agreement Deliver Faster Merger Clearances?
Axinn Viewpoints
Antitrust
Why U.S. Regulators Are Cracking Down on Private Equity Investments in the Healthcare Sector
Byline Articles
Antitrust
Women Leaders in Life Sciences Law
Speaking Engagement
Litigation & Trials
American Bar Association: Inside Antitrust Enforcement—Former Government Perspectives
Webinar
Antitrust
What's the Skinny on SCOTUS' Skinny Label Decision?
Webinar
Intellectual Property
National Bar Association Corporate Counsel Leadership Summit
Speaking Engagement
Antitrust